PerkinElmer, Inc.


$115.24 USD

-$1.06 (-0.91%)

Average Volume
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
Year High
Year Low
Payout Ratio
Current Ratio

Industry, Sector & symbol

Stock Exchange New York Stock Exchange
CEO Dr. Prahlad R. Singh Ph.D.
Industry Diagnostics & Research
Sector Healthcare
Current Symbol PKI
CUSIP 714046109
CIK 0000031791
Phone 781 663 6900
Currency USD
Employees 16700
Country US


Debt-to-Equity Ratio 0.57
Payout Ratio 0.10
Current Ratio 2.58
Quick Ratio 1.97
Cash Ratio 0.97

Sales & Book Value

Annual Sales $3.31B
Price / Sales 5.10
Cash Flow 2.41
Price / Cash Flow 47.80
Price / Book 1.84

Price Target and Rating

Average Stock Price Forecast $164.00
High Stock Price Forecast $202.00
Low Stock Price Forecast $145.00
Forecast Upside/Downside -29.73%
Consensus Rating Buy
Rating Score(0-5) 4
Research Coverage 11 Analysts


EPS (Most Recent Fiscal Year) $4.58
Trailing P/E Ratio 57.06
PEG Ratio -1.31
P/E Growth -1.31
Net Income $579.18M
Net Margin 8.93%
Pretax Margin 11.34%
Return on Equity 3.34%
Return on Assets 1.78%

Financials Score

AltmanZ Score 2.38
Piotroski Score 8.00
Working Capital 2.16B
Total Assets 14.22B
Ebit 375.72M
Market Cap 14.46B
Total Liabilities 6.35B

Poll Results

About PerkinElmer, Inc. (NYSE:PKI) Stock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to f ... armers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

PerkinElmer (PKI) Q1 Earnings Surpass Estimates

2023-05-11 08:24:12

PerkinElmer (PKI) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $2.41 per share a year ago.

Is a Surprise Coming for Revvity (PKI) This Earnings Season?

2023-05-10 09:55:48

Revvity (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?

2023-05-08 09:54:55

Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

Will PerkinElmer (PKI) Beat Estimates Again in Its Next Earnings Report?

2023-04-28 13:39:18

PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

PerkinElmer (PKI) Completes Divestment, New Business Name in Q2

2023-03-14 09:58:17

PerkinElmer (PKI) completes separation of its businesses into two entities ??? the AES business, and the Life Sciences and Diagnostics business.

Frequently Asked Questions

What is the current PerkinElmer, Inc. (PKI) stock price?

PerkinElmer, Inc.(NYSE:PKI) stock price is $115.24 in the last trading session. During the trading session, PKI stock reached the peak price of $170.0 while $113.17 was the lowest point it dropped to. The percentage change in PKI stock occurred in the recent session was --0.91% while the dollar amount for the price change in PKI stock was -$-1.06.

PKI's industry and sector of operation?

The NYSE listed PKI is part of Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of PKI?

Dr. Prahlad R. Singh Ph.D. | Chief Executive Officer, Pres & Director
Ms. Miriame Victor | Senior Vice President & Chief Commercial Officer
Mr. Tajinder Vohra | Senior Vice President of Global Operations
Mr. Maxwell Krakowiak | Senior Vice President & Chief Financial Officer
Mr. Robert Francis Friel | Advisor

How many employees does PKI have?

Number of PKI employees currently stands at 16700. PKI operates from 940 Winter Street, Waltham, MA 02451, US.

Link for PKI official website?

Official Website of PKI is:

How do I contact PKI?

PKI could be contacted at phone #781 663 6900 and can also be accessed through its website. PKI operates from 940 Winter Street, Waltham, MA 02451, US.

How many shares of PKI are traded daily?

The average number of PKI shares traded daily for last 3 months was 808.39K.

What is the market cap of PKI currently?

The market value of PKI currently stands at $14.46B with its latest stock price at $115.24